Abstract
The complement system, including complement components 3 and 4 (C3, C4), traditionally has been linked to innate immunity. More recently, complement components have also been implicated in brain development and the risk of schizophrenia. Based on a large, population-based case-cohort study, we measured the blood concentrations of C3 and C4 in 68,768 neonates. We found a strong correlation between the concentrations of C3 and C4 (phenotypic correlation = 0.65, P-value < 1.0×10−100, genetic correlation = 0.38, P-value = 1.9×10−35). A genome-wide association study (GWAS) for C4 protein concentration identified 36 independent loci, 30 of which were in or near the major histocompatibility complex on chromosome 6 (which includes the C4 gene), while six loci were found on six other chromosomes. A GWAS for C3 identified 15 independent loci, seven of which were located in the C3 gene on chromosome 19, and eight loci on five other chromosomes. We found no association between (a) measured neonatal C3 and C4 concentrations, imputed C4 haplotypes, or predicted C4 gene expression, with (b) schizophrenia (SCZ), bipolar disorder (BIP), depression (DEP), autism spectrum disorder, attention deficit hyperactivity disorder or anorexia nervosa diagnosed in later life. Mendelian randomisation (MR) suggested a small positive association between higher C4 protein concentration and an increased risk of SCZ, BIP, and DEP, but these findings did not persist in more stringent analyses. Evidence from MR supported causal relationships between C4 concentration and several autoimmune disorders: systemic lupus erythematosus (SLE, OR and 95% confidence interval, 0.37, 0.34 – 0.42); type-1 diabetes (T1D, 0.54, 0.50 - 0.58); multiple sclerosis (MS, 0.68, 0.63 - 0.74); rheumatoid arthritis (0.85, 0.80 - 0.91); and Crohn’s disease (1.26, 1.19 - 1.34). A phenome-wide association study (PheWAS) in UK Biobank confirmed that the genetic correlates of C4 concentration were associated a range of autoimmune disorders including coeliac disease, thyrotoxicosis, hypothyroidism, T1D, sarcoidosis, psoriasis, SLE and ankylosing spondylitis. We found no evidence of associations between C3 versus mental or autoimmune disorders based on either MR or PheWAS. In general, our results do not support the hypothesis that C4 is causally associated with the risk of SCZ (nor several other mental disorders). We provide new evidence to support the hypothesis that higher C4 concentration is associated with lower risks of autoimmune disorders.
Competing Interest Statement
CM Bulik reports: Shire (grant recipient, Scientific Advisory Board member); Lundbeckfonden (grant recipient); Pearson (author, royalty recipient); Equip Health Inc. (Clinical Advisory Board); Other authors have nothing to disclose.
Funding Statement
This study was supported by the Danish National Research Foundation, via a Niels Bohr Professorship to John McGrath. Bjarni Vilhjalmsson was also supported by a Lundbeck Foundation Fellowship (R335-2019-2339). This research was conducted using the Danish National Biobank resource, supported by the Novo Nordisk Foundation. The iPSYCH team was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003), NIMH (1R01MH124851-01 to A.D.B.) and the Universities and University Hospitals of Aarhus and Copenhagen. High-performance computer capacity for handling and statistical analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Center for Genomics and Personalized Medicine and the Centre for Integrative Sequencing, iSEQ, Aarhus University, Denmark (grant to ADB). The Anorexia Nervosa Genetics Initiative (ANGI) was an initiative of the Klarman Family Foundation. Genotyping of the Anorexia patients were funded by the Klarman Family Foundation. MEB was supported by the Independent Research Fund Denmark (grant number, 7025-00078B) and by an unrestricted grant from The Lundbeck Foundation (grant number, R268-2016-3925); JCD was supported by a grant from the Danish Council for Independent Research (grant number, 0134-00227B); AFM was supported by an ARC Future Fellowship (FT200100837); KLM was supported by grants from The Lundbeck Foundation and the Brain & Behavior Research Foundation; NRW was supported by NHMRC 1173790 and 1113400. CMB Is supported by NIMH (R56MH129437; R01MH120170; R01MH124871; R01MH119084; R01MH118278; R01 MH124871); Brain and Behavior Research Foundation Distinguished Investigator Grant; Swedish Research Council (Vetenskapsradet, award: 538-2013-8864); Lundbeck Foundation (Grant no. R276-2018-4581).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Material from the Danish Neonatal Screening Biobank has been used primarily for screening for congenital disorders, but are also stored for follow-up diagnostics, screening, quality control and research. According to Danish legislation, material from The Danish Neonatal Screening Biobank can be used for research after approval from the Biobank, and the relevant Scientific Ethical Committee. There is also a mechanism in place ensuring that one can opt out of having the stored material used for research. The Danish Data Protection Agency and the Danish Health Data Authority approved this study. According to Danish law, informed consent is not required for register-based studies. All data accessed were deidentified.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Owing to the sensitive nature of these data, individual level data can be accessed only through secure servers where download of individual level information is prohibited. Each scientific project must be approved before initiation, and approval is granted to a specific Danish research institution. International researchers may gain data access through collaboration with a Danish research institution. More information about getting access to the iPSYCH data can be obtained at https://ipsych.au.dk/about-ipsych/. The summary statistics from the GWAS for C3 and C4 and related analyses will be made available via the GWAS Catalogue https://www.ebi.ac.uk/gwas/ (Accession numbers to follow).
